Shopping Cart 0
Cart Subtotal
USD 0

Prostate Cancer Treatment Market by Drug Type (Chemotherapy, Biological Therapy, Hormone Therapy, and Others) and Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2019-2026

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 5370

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 8995

Details

The global prostate cancer treatment market was valued at USD 6,887 million in 2018, and is projected to reach USD 9,904 million by 2026, registering a CAGR of 4.6% from 2019 to 2026.
 
Prostate cancer is a type of cancer that develops in the male reproductive system. It is asymptomatic, and grow slowly at its earliest stages. Furthermore, it is the second most common cancer in male after skin cancer. In case of treatment, the initial stage of prostate cancer are treated by radiation therapy, and for the last stages, where tumor has spread beyond the prostate gland, drug therapies are recommended. The drug therapies include chemotherapy, biological therapy, and hormone therapy. Xtandi and Zytiga are the major therapeutic drugs that are used for the treatment of prostate cancer.
 
Significant increase in prevalence of prostate cancer, rise in geriatric population, surge in awareness among people regarding the treatment of prostate cancer, increase in demand for prostate cancer treatment products, and rise in uptake of hormonal agents in non-metastatic castration resistant (nmCRPC) & metastatic hormone nave (mHNPC) prostate cancer settings are the key factors that fuel the growth of the prostate cancer treatment market. Moreover, availability of new prostate cancer treatments, strong emerging pipeline drugs, improved R&D investment by drug innovators, enhanced diagnosis & incidence rates in developed economies, increase in generic products, and rise in pharmaceutical industries & diagnostic centers across the globe contribute toward the growth of the market. However, prolonged treatment durations and poor demand for prostate cancer treatment drugs in underdeveloped countries are expected to hinder the growth of the market.
 
The prostate cancer treatment market is segmented on the basis of drug type, distribution channel, and region. By drug type, the market is categorized into chemotherapy, biological therapy, hormone therapy, and others. Depending on distribution channel, the market is classified into hospitals pharmacies, drug stores & retail pharmacies, and online pharmacies. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
 
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
 
KEY MARKET SEGMENTS
By Drug Type
Chemotherapy
Biological Therapy
Hormone Therapy
Others
 
By Distribution Channel
Hospitals Pharmacies
Drug Stores & Retail Pharmacies
Online Pharmacies
 
By Region
 
North America
o U.S.
o Canada
o Mexico
Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
Asia-Pacific
o Japan
o China
o Australia
o India
o South Korea
o Rest of Asia-Pacific
LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
Astellas Pharma Inc.
AstraZeneca plc
Bayer AG
Bristol-Myers Squibb Company
F. Hoffmann-La Roche AG
Ferring Pharmaceuticals Inc.
GlaxoSmithKline Plc
Ipsen Pharma
Johnson & Johnson
Takeda Pharmaceutical Company Ltd
 
 
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
Tolmar Inc.
Indevus Pharmaceuticals
Sanofi S.A.
 
 
READ MORE

Table Of Content

Scope

Chapter 1: Introduction

 

1.1. Report Description

1.2. Key Benefits For Stakeholders

1.3. Key Market Segments

 

1.3.1. List of Key Players Profiled In The Report

 

1.4. Research Methodology

 

1.4.1. Secondary Research

1.4.2. Primary Research

1.4.3. Analyst Tools And Models

 

Chapter 2: Executive Summary

 

2.1. Key Findings of The Study

2.2. Cxo Perspective

 

Chapter 3: Market Overview

 

3.1. Market Definition And Scope

3.2. Key Findings

 

3.2.1. Top Investment Pockets

3.2.2. Market Player Positioning, 2018

 

3.3. Porter'S Five Force Analysis

3.4. Market Dynamics

 

3.4.1. Drivers

 

3.4.1.1. Increase In Prevalence of Prostate Cancer

3.4.1.2. Rise In In Geriatric Population

3.4.1.3. Increase In Government Expenditure On Healthcare

 

3.4.2. Restraint

 

3.4.2.1. Adverse Effects Associated With The Use Prostate Cancer Treatment Drugs

 

3.4.3. Opportunities

 

3.4.3.1. Growth Opportunities In Emerging Markets

 

3.4.4. Impact Analysis

 

Chapter 4: Prostate Cancer Treatment Market, By Drug Type

 

4.1. Overview

 

4.1.1. Market Size And Forecast

 

4.2. Hormone Therapy

 

4.2.1. Key Market Trends, Growth Factors, And Opportunities

4.2.2. Market Size And Forecast, By Region

4.2.3. Market Analysis, By Country

 

4.3. Biological Therapy

 

4.3.1. Key Market Trends, Growth Factors, And Opportunities

4.3.2. Market Size And Forecast

4.3.3. Market Analysis, By Country

 

4.4. Chemotherapy

 

4.4.1. Key Market Trends, Growth Factors, And Opportunities

4.4.2. Market Size And Forecast

4.4.3. Market Analysis, By Country

 

4.5. Others

 

4.5.1. Key Market Trends, Growth Factors, And Opportunities

4.5.2. Market Size And Forecast

4.5.3. Market Analysis, By Country

 

Chapter 5: Prostate Cancer Treatment Market, By Distribution Channel

 

5.1. Overview

 

5.1.1. Market Size And Forecast

 

5.2. Hospital Pharmacy

 

5.2.1. Market Size And Forecast

5.2.2. Market Analysis, By Country

 

5.3. Drug Stores & Retail Pharmacy

 

5.3.1. Market Size And Forecast

5.3.2. Market Analysis, By Country

 

5.4. Online Pharmacy

 

5.4.1. Market Size And Forecast

5.4.2. Market Analysis, By Country

 

Chapter 6: Prostate Cancer Treatment Market, By Region

 

6.1. Overview

 

6.1.1. Market Size And Forecast

 

6.2. North America

 

6.2.1. Key Market Trends, Growth Factors, And Opportunities

6.2.2. Market Size And Forecast, By Country

 

6.2.2.1. U.S.

 

6.2.2.1.1. U.S. Prostate Cancer Treatment Market, By Drug Type

6.2.2.1.2. U.S. Prostate Cancer Treatment Market, By Distribution Channel

 

6.2.2.2. Canada

 

6.2.2.2.1. Canada Prostate Cancer Treatment Market, By Drug Type

6.2.2.2.2. Canada Prostate Cancer Treatment Market, By Distribution Channel

 

6.2.2.3. Mexico

 

6.2.2.3.1. Mexico Prostate Cancer Treatment Market, By Drug Type

6.2.2.3.2. Mexico Prostate Cancer Treatment Market, By Distribution Channel

 

6.2.3. North America Market Size And Forecast, By Drug Type

6.2.4. North America Market Size And Forecast, By Distribution Channel

 

6.3. Europe

 

6.3.1. Key Market Trends, Growth Factors, And Opportunities

6.3.2. Market Size And Forecast, By Country

 

6.3.2.1. Germany

 

6.3.2.1.1. Germany Prostate Cancer Treatment Market, By Drug Type

6.3.2.1.2. Germany Prostate Cancer Treatment Market, By Distribution Channel

 

6.3.2.2. France

 

6.3.2.2.1. France Prostate Cancer Treatment Market, By Drug Type

6.3.2.2.2. France Prostate Cancer Treatment Market, By Distribution Channel

 

6.3.2.3. Uk

 

6.3.2.3.1. Uk Prostate Cancer Treatment Market, By Drug Type

6.3.2.3.2. Uk Prostate Cancer Treatment Market, By Distribution Channel

 

6.3.2.4. Italy

 

6.3.2.4.1. Italy Prostate Cancer Treatment Market, By Drug Type

6.3.2.4.2. Italy Prostate Cancer Treatment Market, By Distribution Channel

 

6.3.2.5. Spain

 

6.3.2.5.1. Spain Prostate Cancer Treatment Market, By Drug Type

6.3.2.5.2. Spain Prostate Cancer Treatment Market, By Distribution Channel

 

6.3.2.6. Rest of Europe

 

6.3.2.6.1. Rest of Europe Prostate Cancer Treatment Market, By Drug Type

6.3.2.6.2. Rest of Europe Prostate Cancer Treatment Market, By Distribution Channel

 

6.3.3. Europe Market Size And Forecast, By Drug Type

6.3.4. Europe Market Size And Forecast, By Distribution Channel

 

6.4. Asia-Pacific

 

6.4.1. Key Market Trends, Growth Factors, And Opportunities

6.4.2. Market Size And Forecast, By Country

 

6.4.2.1. Japan

 

6.4.2.1.1. Japan Prostate Cancer Treatment Market, By Drug Type

6.4.2.1.2. Japan Prostate Cancer Treatment Market, By Distribution Channel

 

6.4.2.2. China

 

6.4.2.2.1. China Prostate Cancer Treatment Market, By Drug Type

6.4.2.2.2. China Prostate Cancer Treatment Market, By Distribution Channel

 

6.4.2.3. Australia

 

6.4.2.3.1. Australia Prostate Cancer Treatment Market, By Drug Type

6.4.2.3.2. Australia Prostate Cancer Treatment Market, By Distribution Channel

 

6.4.2.4. India

 

6.4.2.4.1. India Prostate Cancer Treatment Market, By Drug Type

6.4.2.4.2. India Prostate Cancer Treatment Market, By Distribution Channel

 

6.4.2.5. South Korea

 

6.4.2.5.1. South Korea Prostate Cancer Treatment Market, By Drug Type

6.4.2.5.2. South Korea Prostate Cancer Treatment Market, By Distribution Channel

 

6.4.2.6. Rest of Asia-Pacific

 

6.4.2.6.1. Rest of Asia-Pacific Prostate Cancer Treatment Market, By Drug Type

6.4.2.6.2. Rest of Asia-Pacific Prostate Cancer Treatment Market, By Distribution Channel

 

6.4.3. Asia-Pacific Market Size And Forecast, By Drug Type

6.4.4. Asia-Pacific Market Size And Forecast, By Distribution Channel

 

6.5. Lamea

 

6.5.1. Key Market Trends, Growth Factors, And Opportunities

6.5.2. Market Size And Forecast, By Country

 

6.5.2.1. Brazil

 

6.5.2.1.1. Brazil Prostate Cancer Treatment Market, By Drug Type

6.5.2.1.2. Brazil Prostate Cancer Treatment Market, By Distribution Channel

 

6.5.2.2. Saudi Arabia

 

6.5.2.2.1. Saudi Arabia Prostate Cancer Treatment Market, By Drug Type

6.5.2.2.2. Saudi Arabia Prostate Cancer Treatment Market, By Distribution Channel

 

6.5.2.3. South Africa

 

6.5.2.3.1. South Africa Prostate Cancer Treatment Market, By Drug Type

6.5.2.3.2. South Africa Prostate Cancer Treatment Market, By Distribution Channel

 

6.5.2.4. Rest of Lamea

 

6.5.2.4.1. Rest of Lamea Prostate Cancer Treatment Market, By Drug Type

6.5.2.4.2. Rest of Lamea Prostate Cancer Treatment Market, By Distribution Channel

 

6.5.3. Lamea Market Size And Forecast, By Drug Type

6.5.4. Lamea Market Size And Forecast, By Distribution Channel

 

Chapter 7: Company Profiles

 

7.1. Astellas Pharma Inc.

 

7.1.1. Company Overview

7.1.2. Company Snapshot

7.1.3. Operating Business Segments

7.1.4. Product Portfolio

7.1.5. Business Performance

 

7.2. Astrazeneca Plc

 

7.2.1. Company Overview

7.2.2. Company Snapshot

7.2.3. Operating Business Segments

7.2.4. Product Portfolio

7.2.5. Business Performance

 

7.3. Bayer Ag.

 

7.3.1. Company Overview

7.3.2. Operating Business Segments

7.3.3. Product Portfolio

7.3.4. Business Performance

7.3.5. Key Strategic Moves And Developments

 

7.4. Bristol-Myers Squibb Company

 

7.4.1. Company Overview

7.4.2. Company Snapshot

7.4.3. Operating Business Segments

7.4.4. Product Portfolio

7.4.5. Business Performance

 

7.5. F. Hoffmann-La Roche Ag

 

7.5.1. Company Overview

7.5.2. Company Snapshot

7.5.3. Operating Business Segments

7.5.4. Product Portfolio

7.5.5. Business Performance

 

7.6. Ferring Pharmaceuticals Inc.

 

7.6.1. Company Overview

7.6.2. Company Snapshot

7.6.3. Operating Business Segments

7.6.4. Product Portfolio

7.6.5. Business Performance

 

7.7. Glaxosmithkline Plc.

 

7.7.1. Company Overview

7.7.2. Operating Business Segments

7.7.3. Product Portfolio

7.7.4. Business Performance

 

7.8. Ipsen Pharma

 

7.8.1. Company Overview

7.8.2. Company Snapshot

7.8.3. Operating Business Segments

7.8.4. Product Portfolio

7.8.5. Business Performance

 

7.9. Johnson & Johnson

 

7.9.1. Company Overview

7.9.2. Company Snapshot

7.9.3. Operating Business Segments

7.9.4. Product Portfolio

7.9.5. Business Performance

7.9.6. Key Strategic Moves And Developments: Global

 

7.10. Takeda Pharmaceutical Company Ltd

 

7.10.1. Company Overview

7.10.2. Company Snapshot

7.10.3. Operating Business Segments

7.10.4. Product Portfolio

7.10.5. Business Performance


List Of Figure

List of Figures

 

Figure 01. Global Prostate Cancer Treatment Market Segmentation

Figure 02. Top Investment Pockets

Figure 03. Market Player Positioning, 2018

Figure 04. High Bargaining Power of Suppliers

Figure 05. Moderate Bargaining Power of Buyers

Figure 06. Moderate Threat of Substitutes

Figure 07. Moderate Threat of New Entrants

Figure 08. High Intensity of Rivalry

Figure 09. Impact Analysis

Figure 10. Comparative Analysis of Hormone Therapy Prostate Cancer Treatment Market, By Country, 2018 & 2026 (USD Million)

Figure 11. Comparative Analysis of Biological Therapy Prostate Cancer Treatment Market, By Country, 2018 & 2026 (USD Million)

Figure 12. Comparative Analysis of Chemotherapy Prostate Cancer Treatment Market, By Country, 2018 & 2026 (USD Million)

Figure 13. Comparative Analysis of Others Prostate Cancer Treatment Market, By Country, 2018 & 2026 (USD Million)

Figure 14. Comparative Analysis of Hospital Pharmacy Prostate Cancer Treatment Market, By Country, 2018 & 2026 (USD Million)

Figure 15. Comparative Analysis Drug Stores & Retail Pharmacy Prostate Cancer Treatment Market, By Country, 2018 & 2026 (%)

Figure 16. Comparative Analysis of Online Pharmacy Prostate Cancer Treatment Market, By Country, 2018 & 2026 (%)

Figure 17. Astellas: Net Sales, 2016-2018 (USD Million)

Figure 18. Astellas: Revenue Share By Segment, 2018 (%)

Figure 19. Astellas: Revenue Share By Region, 2018 (%)

Figure 20. Astrazeneca: Net Sales, 2016-2018 (USD Million)

Figure 21. Astrazeneca: Revenue Share By Region, 2018(%)

Figure 22. Bayer: Net Sales, 2016-2018 (USD Million)

Figure 23. Bayer: Revenue Share By Segment, 2018 (%)

Figure 24. Bayer: Revenue Share By Region, 2018(%)

Figure 25. Bms: Net Sales, 2016-2018 (USD Million)

Figure 26. Bms: Revenue Share By Region, 2018 (%)

Figure 27. Roche: Net Sales, 2016-2018 (USD Million)

Figure 28. Roche: Revenue Share By Segment, 2018 (%)

Figure 29. Roche: Revenue Share By Region, 2018 (%)

Figure 30. Ferring: Net Sales, 2016-2018 (USD Million)

Figure 31. Ferring: Revenue Share By Segment, 2018(%)

Figure 32. Ferring: Revenue Share By Region, 2018(%)

Figure 33. Gsk: Net Sales, 2016-2018 (USD Million)

Figure 34. Gsk: Revenue Share By Segment, 2018 (%)

Figure 35. Gsk: Revenue Share By Region, 2018(%)

Figure 36. Ipsen: Net Sales, 2016-2018 (USD Million)

Figure 37. Ipsen: Revenue Share By Segments, 2018(%)

Figure 38. Ipsen: Revenue Share By Region, 2018(%)

Figure 39. J&J: Net Sales, 2016-2018 (USD Million)

Figure 40. J&J: Revenue Share By Segment, 2018 (%)

Figure 41. J&J: Revenue Share By Region, 2018(%)

Figure 42. Takeda: Net Sales, 2016-2018 (USD Million)

Figure 43. Takeda: Revenue Share By Region, 2018 (%)

 


List Of Table

List of Tables

 

Table 01. Global Prostate Cancer Treatment Market, By Drug Type, 2018-2026 (USD Million)

Table 02. Hormone Therapy Prostate Cancer Treatment Market, By Region, 2018-2026 (USD Million)

Table 03. Biological Therapy Prostate Cancer Treatment Market, By Region, 2018-2026 (USD Million)

Table 04. Chemotherapy Prostate Cancer Treatment Market, By Region, 2018-2026 (USD Million)

Table 05. Others Prostate Cancer Treatment Market, By Region, 2018-2026 (USD Million)

Table 06. Global Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026 (USD Million)

Table 07. Hospital Pharmacy Prostate Cancer Treatment Market, By Region, 2018-2026 (USD Million)

Table 08. Drug Stores & Retail Pharmacy Prostate Cancer Treatment Market, By Region, 2018-2026 (USD Million)

Table 09. Online Pharmacy Prostate Cancer Treatment Market, By Region, 2018-2026 (USD Million)

Table 10. Prostate Cancer Treatment Market, By Region, 2018-2026 (USD Million)

Table 11. North America Prostate Cancer Treatment Market, By Country, 2018-2026 (USD Million)

Table 12. U.S. Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 13. U.S. Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 14. Canada Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 15. Canada Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 16. Mexico Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 17. Mexico Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 18. North America Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 19. North America Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 20. Europe Prostate Cancer Treatment Market, By Country, 2018-2026 (USD Million)

Table 21. Germany Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 22. Germany Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 23. France Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 24. France Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 25. Uk Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 26. Uk Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 27. Italy Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 28. Italy Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 29. Spain Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 30. Spain Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 31. Rest of Europe Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 32. Rest of Europe Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 33. Europe Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 34. Europe Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 35. Asia-Pacific Prostate Cancer Treatment Market, By Country, 2018-2026 (USD Million)

Table 36. Japan Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 37. Japan Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 38. China Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 39. China Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 40. Australia Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 41. Australia Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 42. India Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 43. India Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 44. South Korea Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 45. South Korea Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 46. Rest of Asia-Pacific Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 47. Rest of Asia-Pacific Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 48. Asia-Pacific Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 49. Asia-Pacific Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 50. Lamea Prostate Cancer Treatment Market, By Country, 2018-2026 (USD Million)

Table 51. Brazil Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 52. Brazil Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 53. Saudi Arabia Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 54. Saudi Arabia Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 55. South Africa Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 56. South Africa Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 57. Rest of Lamea Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 58. Rest of Lamea Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 59. Lamea Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 60. Lamea Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 61. Astellas: Company Snapshot

Table 62. Astellas: Product Portfolio

Table 63. Astrazeneca: Company Snapshot

Table 64. Astrazeneca: Operating Business Segments

Table 65. Astrazeneca: Product Portfolio

Table 66. Bayer.: Company Snapshot

Table 67. Bayer.: Operating Segments

Table 68. Bayer.: Product Portfolio

Table 69. Bms: Company Snapshot

Table 70. Bms: Product Portfolio

Table 71. Roche: Company Snapshot

Table 72. Roche: Operating Segments

Table 73. Roche: Product Portfolio

Table 74. Ferring: Company Snapshot

Table 75. Ferring: Product Business Segment

Table 76. Ferring: Product Portfolio

Table 77. Gsk.: Company Snapshot

Table 78. Gsk.: Operating Business Segments

Table 79. Gsk.: Product Portfolio

Table 80. Ipsen: Company Snapshot

Table 81. Ipsen: Operating Segments

Table 82. Ipsen: Product Portfolio

Table 83. J&J: Company Snapshot

Table 84. J&J: Operating Business Segments

Table 85. J&J: Product Portfolio

Table 86. Takeda: Company Snapshot

Table 87. Takeda: Product Portfolio

Licence Rights

Single-User license:

This  grants one non-exclusive, non-transferable machine-readable license for the report either electronically or online. The right to store, display, use, or stockpile the report is restricted to only ONE authorized computer. For obtaining a single user license, ONLY an individual ("you") for individual use is entitled for using the product or as mentioned in the License Terms. Any individual representing an organization is refrained from accessing the products/services of AMR or as stated in the License Terms; any breach of which shall lead to violation of applicable laws in the United States, India, or in the jurisdiction of purchase. The products and services offered are the intellectual property of AMR, and are protected by applicable copyright laws, international treaty provisions, and other applicable laws of the country in which these are being used. Albeit the abovementioned, you are NOT be permitted to:

transmit or permit any third party to use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to assign the rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial/noncommercial gains

share the information or content either electronically or in printed form with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization or any other unauthorized users.

 

Five-User License:

This  grants up to Five non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online. The right to store, transfer, display, use, or stockpile the report is restricted to only FIVE authorized users. An individual representing an organization or an organization shall ONLY purchase the five-user license. The authorized users can print additional duplicate printed copies of the report for distribution to the employees of his/her company (Personnel). Albeit the abovementioned, you are NOT be permitted to:

 

transmit or permit by any means to any third party (i.e. non-personnel) or unauthorized users for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to redistribute or assign rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; exclusively permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial or noncommercial gains.

share the information or content either electronically or as printed copies with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization, or to more than 5 AUTHORIZED USERS.

 

Enterprise License:

This  grants global, non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online, within the organization and/or its subsidiaries. The authorized users shall have complete right to store, display, transfer, and/or use the report ONLY within the organization or its subsidiaries. Authorized users can take unlimited printed copies of the report for distribution among its employees. Albeit the abovementioned, you shall NOT be permitted to:

transmit or permit by any means to any third party (i.e. non-personnel) for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer or attempt to assign the rights in the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Ferring Pharmaceuticals Inc., GlaxoSmithKline Plc, Ipsen Pharma, Johnson & Johnson, and Takeda Pharmaceutical Company Ltd.

Company Profile

Company Profile Title

The global prostate cancer treatment market was valued at USD 6,887 million in 2018, and is projected to reach USD 9,904 million by 2026, registering a CAGR of 4.6% from 2019 to 2026.
 
Prostate cancer is a type of cancer that develops in the male reproductive system. It is asymptomatic, and grow slowly at its earliest stages. Furthermore, it is the second most common cancer in male after skin cancer. In case of treatment, the initial stage of prostate cancer are treated by radiation therapy, and for the last stages, where tumor has spread beyond the prostate gland, drug therapies are recommended. The drug therapies include chemotherapy, biological therapy, and hormone therapy. Xtandi and Zytiga are the major therapeutic drugs that are used for the treatment of prostate cancer.
 
Significant increase in prevalence of prostate cancer, rise in geriatric population, surge in awareness among people regarding the treatment of prostate cancer, increase in demand for prostate cancer treatment products, and rise in uptake of hormonal agents in non-metastatic castration resistant (nmCRPC) & metastatic hormone nave (mHNPC) prostate cancer settings are the key factors that fuel the growth of the prostate cancer treatment market. Moreover, availability of new prostate cancer treatments, strong emerging pipeline drugs, improved R&D investment by drug innovators, enhanced diagnosis & incidence rates in developed economies, increase in generic products, and rise in pharmaceutical industries & diagnostic centers across the globe contribute toward the growth of the market. However, prolonged treatment durations and poor demand for prostate cancer treatment drugs in underdeveloped countries are expected to hinder the growth of the market.
 
The prostate cancer treatment market is segmented on the basis of drug type, distribution channel, and region. By drug type, the market is categorized into chemotherapy, biological therapy, hormone therapy, and others. Depending on distribution channel, the market is classified into hospitals pharmacies, drug stores & retail pharmacies, and online pharmacies. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
 
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
 
KEY MARKET SEGMENTS
By Drug Type
Chemotherapy
Biological Therapy
Hormone Therapy
Others
 
By Distribution Channel
Hospitals Pharmacies
Drug Stores & Retail Pharmacies
Online Pharmacies
 
By Region
 
North America
o U.S.
o Canada
o Mexico
Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
Asia-Pacific
o Japan
o China
o Australia
o India
o South Korea
o Rest of Asia-Pacific
LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
Astellas Pharma Inc.
AstraZeneca plc
Bayer AG
Bristol-Myers Squibb Company
F. Hoffmann-La Roche AG
Ferring Pharmaceuticals Inc.
GlaxoSmithKline Plc
Ipsen Pharma
Johnson & Johnson
Takeda Pharmaceutical Company Ltd
 
 
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
Tolmar Inc.
Indevus Pharmaceuticals
Sanofi S.A.
 
 
READ MORE

Scope

Chapter 1: Introduction

 

1.1. Report Description

1.2. Key Benefits For Stakeholders

1.3. Key Market Segments

 

1.3.1. List of Key Players Profiled In The Report

 

1.4. Research Methodology

 

1.4.1. Secondary Research

1.4.2. Primary Research

1.4.3. Analyst Tools And Models

 

Chapter 2: Executive Summary

 

2.1. Key Findings of The Study

2.2. Cxo Perspective

 

Chapter 3: Market Overview

 

3.1. Market Definition And Scope

3.2. Key Findings

 

3.2.1. Top Investment Pockets

3.2.2. Market Player Positioning, 2018

 

3.3. Porter'S Five Force Analysis

3.4. Market Dynamics

 

3.4.1. Drivers

 

3.4.1.1. Increase In Prevalence of Prostate Cancer

3.4.1.2. Rise In In Geriatric Population

3.4.1.3. Increase In Government Expenditure On Healthcare

 

3.4.2. Restraint

 

3.4.2.1. Adverse Effects Associated With The Use Prostate Cancer Treatment Drugs

 

3.4.3. Opportunities

 

3.4.3.1. Growth Opportunities In Emerging Markets

 

3.4.4. Impact Analysis

 

Chapter 4: Prostate Cancer Treatment Market, By Drug Type

 

4.1. Overview

 

4.1.1. Market Size And Forecast

 

4.2. Hormone Therapy

 

4.2.1. Key Market Trends, Growth Factors, And Opportunities

4.2.2. Market Size And Forecast, By Region

4.2.3. Market Analysis, By Country

 

4.3. Biological Therapy

 

4.3.1. Key Market Trends, Growth Factors, And Opportunities

4.3.2. Market Size And Forecast

4.3.3. Market Analysis, By Country

 

4.4. Chemotherapy

 

4.4.1. Key Market Trends, Growth Factors, And Opportunities

4.4.2. Market Size And Forecast

4.4.3. Market Analysis, By Country

 

4.5. Others

 

4.5.1. Key Market Trends, Growth Factors, And Opportunities

4.5.2. Market Size And Forecast

4.5.3. Market Analysis, By Country

 

Chapter 5: Prostate Cancer Treatment Market, By Distribution Channel

 

5.1. Overview

 

5.1.1. Market Size And Forecast

 

5.2. Hospital Pharmacy

 

5.2.1. Market Size And Forecast

5.2.2. Market Analysis, By Country

 

5.3. Drug Stores & Retail Pharmacy

 

5.3.1. Market Size And Forecast

5.3.2. Market Analysis, By Country

 

5.4. Online Pharmacy

 

5.4.1. Market Size And Forecast

5.4.2. Market Analysis, By Country

 

Chapter 6: Prostate Cancer Treatment Market, By Region

 

6.1. Overview

 

6.1.1. Market Size And Forecast

 

6.2. North America

 

6.2.1. Key Market Trends, Growth Factors, And Opportunities

6.2.2. Market Size And Forecast, By Country

 

6.2.2.1. U.S.

 

6.2.2.1.1. U.S. Prostate Cancer Treatment Market, By Drug Type

6.2.2.1.2. U.S. Prostate Cancer Treatment Market, By Distribution Channel

 

6.2.2.2. Canada

 

6.2.2.2.1. Canada Prostate Cancer Treatment Market, By Drug Type

6.2.2.2.2. Canada Prostate Cancer Treatment Market, By Distribution Channel

 

6.2.2.3. Mexico

 

6.2.2.3.1. Mexico Prostate Cancer Treatment Market, By Drug Type

6.2.2.3.2. Mexico Prostate Cancer Treatment Market, By Distribution Channel

 

6.2.3. North America Market Size And Forecast, By Drug Type

6.2.4. North America Market Size And Forecast, By Distribution Channel

 

6.3. Europe

 

6.3.1. Key Market Trends, Growth Factors, And Opportunities

6.3.2. Market Size And Forecast, By Country

 

6.3.2.1. Germany

 

6.3.2.1.1. Germany Prostate Cancer Treatment Market, By Drug Type

6.3.2.1.2. Germany Prostate Cancer Treatment Market, By Distribution Channel

 

6.3.2.2. France

 

6.3.2.2.1. France Prostate Cancer Treatment Market, By Drug Type

6.3.2.2.2. France Prostate Cancer Treatment Market, By Distribution Channel

 

6.3.2.3. Uk

 

6.3.2.3.1. Uk Prostate Cancer Treatment Market, By Drug Type

6.3.2.3.2. Uk Prostate Cancer Treatment Market, By Distribution Channel

 

6.3.2.4. Italy

 

6.3.2.4.1. Italy Prostate Cancer Treatment Market, By Drug Type

6.3.2.4.2. Italy Prostate Cancer Treatment Market, By Distribution Channel

 

6.3.2.5. Spain

 

6.3.2.5.1. Spain Prostate Cancer Treatment Market, By Drug Type

6.3.2.5.2. Spain Prostate Cancer Treatment Market, By Distribution Channel

 

6.3.2.6. Rest of Europe

 

6.3.2.6.1. Rest of Europe Prostate Cancer Treatment Market, By Drug Type

6.3.2.6.2. Rest of Europe Prostate Cancer Treatment Market, By Distribution Channel

 

6.3.3. Europe Market Size And Forecast, By Drug Type

6.3.4. Europe Market Size And Forecast, By Distribution Channel

 

6.4. Asia-Pacific

 

6.4.1. Key Market Trends, Growth Factors, And Opportunities

6.4.2. Market Size And Forecast, By Country

 

6.4.2.1. Japan

 

6.4.2.1.1. Japan Prostate Cancer Treatment Market, By Drug Type

6.4.2.1.2. Japan Prostate Cancer Treatment Market, By Distribution Channel

 

6.4.2.2. China

 

6.4.2.2.1. China Prostate Cancer Treatment Market, By Drug Type

6.4.2.2.2. China Prostate Cancer Treatment Market, By Distribution Channel

 

6.4.2.3. Australia

 

6.4.2.3.1. Australia Prostate Cancer Treatment Market, By Drug Type

6.4.2.3.2. Australia Prostate Cancer Treatment Market, By Distribution Channel

 

6.4.2.4. India

 

6.4.2.4.1. India Prostate Cancer Treatment Market, By Drug Type

6.4.2.4.2. India Prostate Cancer Treatment Market, By Distribution Channel

 

6.4.2.5. South Korea

 

6.4.2.5.1. South Korea Prostate Cancer Treatment Market, By Drug Type

6.4.2.5.2. South Korea Prostate Cancer Treatment Market, By Distribution Channel

 

6.4.2.6. Rest of Asia-Pacific

 

6.4.2.6.1. Rest of Asia-Pacific Prostate Cancer Treatment Market, By Drug Type

6.4.2.6.2. Rest of Asia-Pacific Prostate Cancer Treatment Market, By Distribution Channel

 

6.4.3. Asia-Pacific Market Size And Forecast, By Drug Type

6.4.4. Asia-Pacific Market Size And Forecast, By Distribution Channel

 

6.5. Lamea

 

6.5.1. Key Market Trends, Growth Factors, And Opportunities

6.5.2. Market Size And Forecast, By Country

 

6.5.2.1. Brazil

 

6.5.2.1.1. Brazil Prostate Cancer Treatment Market, By Drug Type

6.5.2.1.2. Brazil Prostate Cancer Treatment Market, By Distribution Channel

 

6.5.2.2. Saudi Arabia

 

6.5.2.2.1. Saudi Arabia Prostate Cancer Treatment Market, By Drug Type

6.5.2.2.2. Saudi Arabia Prostate Cancer Treatment Market, By Distribution Channel

 

6.5.2.3. South Africa

 

6.5.2.3.1. South Africa Prostate Cancer Treatment Market, By Drug Type

6.5.2.3.2. South Africa Prostate Cancer Treatment Market, By Distribution Channel

 

6.5.2.4. Rest of Lamea

 

6.5.2.4.1. Rest of Lamea Prostate Cancer Treatment Market, By Drug Type

6.5.2.4.2. Rest of Lamea Prostate Cancer Treatment Market, By Distribution Channel

 

6.5.3. Lamea Market Size And Forecast, By Drug Type

6.5.4. Lamea Market Size And Forecast, By Distribution Channel

 

Chapter 7: Company Profiles

 

7.1. Astellas Pharma Inc.

 

7.1.1. Company Overview

7.1.2. Company Snapshot

7.1.3. Operating Business Segments

7.1.4. Product Portfolio

7.1.5. Business Performance

 

7.2. Astrazeneca Plc

 

7.2.1. Company Overview

7.2.2. Company Snapshot

7.2.3. Operating Business Segments

7.2.4. Product Portfolio

7.2.5. Business Performance

 

7.3. Bayer Ag.

 

7.3.1. Company Overview

7.3.2. Operating Business Segments

7.3.3. Product Portfolio

7.3.4. Business Performance

7.3.5. Key Strategic Moves And Developments

 

7.4. Bristol-Myers Squibb Company

 

7.4.1. Company Overview

7.4.2. Company Snapshot

7.4.3. Operating Business Segments

7.4.4. Product Portfolio

7.4.5. Business Performance

 

7.5. F. Hoffmann-La Roche Ag

 

7.5.1. Company Overview

7.5.2. Company Snapshot

7.5.3. Operating Business Segments

7.5.4. Product Portfolio

7.5.5. Business Performance

 

7.6. Ferring Pharmaceuticals Inc.

 

7.6.1. Company Overview

7.6.2. Company Snapshot

7.6.3. Operating Business Segments

7.6.4. Product Portfolio

7.6.5. Business Performance

 

7.7. Glaxosmithkline Plc.

 

7.7.1. Company Overview

7.7.2. Operating Business Segments

7.7.3. Product Portfolio

7.7.4. Business Performance

 

7.8. Ipsen Pharma

 

7.8.1. Company Overview

7.8.2. Company Snapshot

7.8.3. Operating Business Segments

7.8.4. Product Portfolio

7.8.5. Business Performance

 

7.9. Johnson & Johnson

 

7.9.1. Company Overview

7.9.2. Company Snapshot

7.9.3. Operating Business Segments

7.9.4. Product Portfolio

7.9.5. Business Performance

7.9.6. Key Strategic Moves And Developments: Global

 

7.10. Takeda Pharmaceutical Company Ltd

 

7.10.1. Company Overview

7.10.2. Company Snapshot

7.10.3. Operating Business Segments

7.10.4. Product Portfolio

7.10.5. Business Performance


List Of Figure

List of Figures

 

Figure 01. Global Prostate Cancer Treatment Market Segmentation

Figure 02. Top Investment Pockets

Figure 03. Market Player Positioning, 2018

Figure 04. High Bargaining Power of Suppliers

Figure 05. Moderate Bargaining Power of Buyers

Figure 06. Moderate Threat of Substitutes

Figure 07. Moderate Threat of New Entrants

Figure 08. High Intensity of Rivalry

Figure 09. Impact Analysis

Figure 10. Comparative Analysis of Hormone Therapy Prostate Cancer Treatment Market, By Country, 2018 & 2026 (USD Million)

Figure 11. Comparative Analysis of Biological Therapy Prostate Cancer Treatment Market, By Country, 2018 & 2026 (USD Million)

Figure 12. Comparative Analysis of Chemotherapy Prostate Cancer Treatment Market, By Country, 2018 & 2026 (USD Million)

Figure 13. Comparative Analysis of Others Prostate Cancer Treatment Market, By Country, 2018 & 2026 (USD Million)

Figure 14. Comparative Analysis of Hospital Pharmacy Prostate Cancer Treatment Market, By Country, 2018 & 2026 (USD Million)

Figure 15. Comparative Analysis Drug Stores & Retail Pharmacy Prostate Cancer Treatment Market, By Country, 2018 & 2026 (%)

Figure 16. Comparative Analysis of Online Pharmacy Prostate Cancer Treatment Market, By Country, 2018 & 2026 (%)

Figure 17. Astellas: Net Sales, 2016-2018 (USD Million)

Figure 18. Astellas: Revenue Share By Segment, 2018 (%)

Figure 19. Astellas: Revenue Share By Region, 2018 (%)

Figure 20. Astrazeneca: Net Sales, 2016-2018 (USD Million)

Figure 21. Astrazeneca: Revenue Share By Region, 2018(%)

Figure 22. Bayer: Net Sales, 2016-2018 (USD Million)

Figure 23. Bayer: Revenue Share By Segment, 2018 (%)

Figure 24. Bayer: Revenue Share By Region, 2018(%)

Figure 25. Bms: Net Sales, 2016-2018 (USD Million)

Figure 26. Bms: Revenue Share By Region, 2018 (%)

Figure 27. Roche: Net Sales, 2016-2018 (USD Million)

Figure 28. Roche: Revenue Share By Segment, 2018 (%)

Figure 29. Roche: Revenue Share By Region, 2018 (%)

Figure 30. Ferring: Net Sales, 2016-2018 (USD Million)

Figure 31. Ferring: Revenue Share By Segment, 2018(%)

Figure 32. Ferring: Revenue Share By Region, 2018(%)

Figure 33. Gsk: Net Sales, 2016-2018 (USD Million)

Figure 34. Gsk: Revenue Share By Segment, 2018 (%)

Figure 35. Gsk: Revenue Share By Region, 2018(%)

Figure 36. Ipsen: Net Sales, 2016-2018 (USD Million)

Figure 37. Ipsen: Revenue Share By Segments, 2018(%)

Figure 38. Ipsen: Revenue Share By Region, 2018(%)

Figure 39. J&J: Net Sales, 2016-2018 (USD Million)

Figure 40. J&J: Revenue Share By Segment, 2018 (%)

Figure 41. J&J: Revenue Share By Region, 2018(%)

Figure 42. Takeda: Net Sales, 2016-2018 (USD Million)

Figure 43. Takeda: Revenue Share By Region, 2018 (%)

 


List Of Table

List of Tables

 

Table 01. Global Prostate Cancer Treatment Market, By Drug Type, 2018-2026 (USD Million)

Table 02. Hormone Therapy Prostate Cancer Treatment Market, By Region, 2018-2026 (USD Million)

Table 03. Biological Therapy Prostate Cancer Treatment Market, By Region, 2018-2026 (USD Million)

Table 04. Chemotherapy Prostate Cancer Treatment Market, By Region, 2018-2026 (USD Million)

Table 05. Others Prostate Cancer Treatment Market, By Region, 2018-2026 (USD Million)

Table 06. Global Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026 (USD Million)

Table 07. Hospital Pharmacy Prostate Cancer Treatment Market, By Region, 2018-2026 (USD Million)

Table 08. Drug Stores & Retail Pharmacy Prostate Cancer Treatment Market, By Region, 2018-2026 (USD Million)

Table 09. Online Pharmacy Prostate Cancer Treatment Market, By Region, 2018-2026 (USD Million)

Table 10. Prostate Cancer Treatment Market, By Region, 2018-2026 (USD Million)

Table 11. North America Prostate Cancer Treatment Market, By Country, 2018-2026 (USD Million)

Table 12. U.S. Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 13. U.S. Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 14. Canada Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 15. Canada Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 16. Mexico Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 17. Mexico Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 18. North America Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 19. North America Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 20. Europe Prostate Cancer Treatment Market, By Country, 2018-2026 (USD Million)

Table 21. Germany Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 22. Germany Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 23. France Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 24. France Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 25. Uk Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 26. Uk Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 27. Italy Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 28. Italy Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 29. Spain Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 30. Spain Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 31. Rest of Europe Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 32. Rest of Europe Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 33. Europe Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 34. Europe Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 35. Asia-Pacific Prostate Cancer Treatment Market, By Country, 2018-2026 (USD Million)

Table 36. Japan Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 37. Japan Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 38. China Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 39. China Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 40. Australia Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 41. Australia Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 42. India Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 43. India Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 44. South Korea Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 45. South Korea Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 46. Rest of Asia-Pacific Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 47. Rest of Asia-Pacific Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 48. Asia-Pacific Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 49. Asia-Pacific Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 50. Lamea Prostate Cancer Treatment Market, By Country, 2018-2026 (USD Million)

Table 51. Brazil Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 52. Brazil Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 53. Saudi Arabia Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 54. Saudi Arabia Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 55. South Africa Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 56. South Africa Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 57. Rest of Lamea Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 58. Rest of Lamea Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 59. Lamea Prostate Cancer Treatment Market, By Drug Type, 2018-2026

Table 60. Lamea Prostate Cancer Treatment Market, By Distribution Channel, 2018-2026

Table 61. Astellas: Company Snapshot

Table 62. Astellas: Product Portfolio

Table 63. Astrazeneca: Company Snapshot

Table 64. Astrazeneca: Operating Business Segments

Table 65. Astrazeneca: Product Portfolio

Table 66. Bayer.: Company Snapshot

Table 67. Bayer.: Operating Segments

Table 68. Bayer.: Product Portfolio

Table 69. Bms: Company Snapshot

Table 70. Bms: Product Portfolio

Table 71. Roche: Company Snapshot

Table 72. Roche: Operating Segments

Table 73. Roche: Product Portfolio

Table 74. Ferring: Company Snapshot

Table 75. Ferring: Product Business Segment

Table 76. Ferring: Product Portfolio

Table 77. Gsk.: Company Snapshot

Table 78. Gsk.: Operating Business Segments

Table 79. Gsk.: Product Portfolio

Table 80. Ipsen: Company Snapshot

Table 81. Ipsen: Operating Segments

Table 82. Ipsen: Product Portfolio

Table 83. J&J: Company Snapshot

Table 84. J&J: Operating Business Segments

Table 85. J&J: Product Portfolio

Table 86. Takeda: Company Snapshot

Table 87. Takeda: Product Portfolio

Single-User license:

This  grants one non-exclusive, non-transferable machine-readable license for the report either electronically or online. The right to store, display, use, or stockpile the report is restricted to only ONE authorized computer. For obtaining a single user license, ONLY an individual ("you") for individual use is entitled for using the product or as mentioned in the License Terms. Any individual representing an organization is refrained from accessing the products/services of AMR or as stated in the License Terms; any breach of which shall lead to violation of applicable laws in the United States, India, or in the jurisdiction of purchase. The products and services offered are the intellectual property of AMR, and are protected by applicable copyright laws, international treaty provisions, and other applicable laws of the country in which these are being used. Albeit the abovementioned, you are NOT be permitted to:

transmit or permit any third party to use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to assign the rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial/noncommercial gains

share the information or content either electronically or in printed form with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization or any other unauthorized users.

 

Five-User License:

This  grants up to Five non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online. The right to store, transfer, display, use, or stockpile the report is restricted to only FIVE authorized users. An individual representing an organization or an organization shall ONLY purchase the five-user license. The authorized users can print additional duplicate printed copies of the report for distribution to the employees of his/her company (Personnel). Albeit the abovementioned, you are NOT be permitted to:

 

transmit or permit by any means to any third party (i.e. non-personnel) or unauthorized users for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to redistribute or assign rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; exclusively permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial or noncommercial gains.

share the information or content either electronically or as printed copies with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization, or to more than 5 AUTHORIZED USERS.

 

Enterprise License:

This  grants global, non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online, within the organization and/or its subsidiaries. The authorized users shall have complete right to store, display, transfer, and/or use the report ONLY within the organization or its subsidiaries. Authorized users can take unlimited printed copies of the report for distribution among its employees. Albeit the abovementioned, you shall NOT be permitted to:

transmit or permit by any means to any third party (i.e. non-personnel) for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer or attempt to assign the rights in the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Ferring Pharmaceuticals Inc., GlaxoSmithKline Plc, Ipsen Pharma, Johnson & Johnson, and Takeda Pharmaceutical Company Ltd.